Device Trial Radar · NCT02854319
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
Last checked: Nov 20, 2026Latest source record: May 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Sep 7, 2016
Primary completion
Oct 25, 2016
Study completion Mar 13, 2018
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Aug 3, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the REPRISE EDGE study is to confirm the acute performance and safety of the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set for transcatheter aortic valve implantation (TAVI) in symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.
Conditions
- Aortic Valve Stenosis
Interventions
LOTUS Edge Valve SystemDevice
Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean aortic valve pressure gradientTime frame: At discharge from hospital or at 7 days post-procedure (whichever comes first)
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Clinique Pasteur
Toulouse, France
Skåne University Hospital
Lund, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.